Uncategorized

Cancer remains Hong Kong’s number one killer, claiming more than 14,000 lives every year, the majority due to metastasis (Hong Kong Cancer Registry, 2023). With advances in medical technology, circulating tumor cell (CTC) testing has emerged as a powerful new tool for cancer diagnosis and treatment monitoring. However, numerous CTC testing technologies are now available on the market. For patients, choosing the most suitable and reliable test is a practical and critical decision.

The core reason cancer is so difficult to completely cure lies in metastasis. Even if the primary tumor is surgically removed or shrunk, residual cancer cells that disseminate outward and take root in distant organs can trigger new tumors, becoming the leading cause of death. From the patient’s perspective, we’ll use straightforward analogies and scientific mechanisms here to explain why this is so challenging, as well as the possibilities and limitations of detecting circulating tumor cells (CTCs) in the blood.

In Hong Kong, cancer has topped the list of the ten leading causes of death for many consecutive years. Whether it is lung cancer, colorectal cancer, breast cancer, or liver cancer, the battle is long and grueling for both patients and their families. Most patients recall that their diagnosis came only when symptoms were obvious or when the tumor had already grown to a detectable size. This feeling of “finding out too late” is an almost universal source of anxiety among cancer patients.

Cancer is one of the leading causes of death in Hong Kong. According to data from the Hong Kong Cancer Registry, cancer claims more than 14,000 lives every year, with the vast majority of these deaths caused by metastasis. In recent years, with advances in medical technology, the detection of circulating tumor cells (CTCs) has gained increasing attention and is regarded as an important new tool for cancer diagnosis, monitoring, and prognosis. This article explores the significance and clinical value of CTC testing from the perspective of patients in Hong Kong.